Welcome to our dedicated page for Reshape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on Reshape Lifesciences stock.
Reshape Lifesciences Inc. (RSLS) is a medical device innovator focused on non-surgical solutions for weight management and metabolic health. This page provides investors and healthcare professionals with essential updates on corporate milestones, product developments, and clinical advancements.
Access timely announcements including regulatory approvals, strategic partnerships, and clinical trial outcomes. Our curated news feed helps stakeholders track the company’s progress in advancing alternatives to invasive obesity treatments and diabetes management technologies.
Key coverage areas include product innovation updates, financial disclosures, and market expansion initiatives. Bookmark this page for structured access to RSLS’s evolving role in the medical device sector, with neutral reporting suitable for both casual observers and professional analysts.
ReShape Lifesciences (Nasdaq: RSLS) reported a 20.4% revenue increase to $13.6 million for 2021, driven by marketing efforts and improved consumer demand. Key achievements included debt elimination, raising $46 million, and enhancing direct-to-consumer campaigns, resulting in a 331% rise in website traffic. Gross profit rose to $8.3 million, reflecting a 61.4% margin. However, total operating expenses increased significantly to $64.8 million due to stock compensation and merger costs. The CEO expressed optimism for continued revenue growth as healthcare restrictions ease.
ReShape Lifesciences (RSLS) reports substantial growth in patient engagement following the launch of its direct-to-consumer marketing campaign in October 2021. The company noted a remarkable increase of 250,000 visits to its website and over 900% more inquiries regarding the Lap-Band procedure. Doctor referrals have surged nearly 400%, indicating strong market interest. As insurers are reducing mandatory wait times and expanding coverage for bariatric procedures across multiple states, ReShape anticipates a significant rise in revenue. The campaign is also featured in various major publications and cable networks.
ReShape Lifesciences (Nasdaq: RSLS) reported an impressive 20% revenue increase for the year ended December 31, 2021, rising from $11.3 million to $13.6 million. The company improved its financial position by eliminating all debt, including a $3 million liability to Apollo Endosurgery related to the purchase of the Lap-Band. As of year-end, ReShape held $22.8 million in cash and cash equivalents. A webcast to discuss financial results and updates will occur on March 28, 2022.
ReShape Lifesciences (Nasdaq: RSLS) announces its participation in two upcoming investor conferences in March. The first, the Oppenheimer 32nd Annual Virtual Healthcare Conference, runs from March 15-17, with CEO Bart Bandy presenting on March 16 at 2:00 PM ET. The Maxim 2nd Annual Virtual Growth Conference follows on March 28-29, featuring a fireside chat with Mr. Bandy on March 28 at 4:30 PM ET. Live broadcasts and replays will be accessible on the company's website. Management will also hold one-on-one meetings during these events.
ReShape Lifesciences (Nasdaq: RSLS) is set to present its next-generation Lap-Band® Program and reshape
ReShape Lifesciences (Nasdaq: RSLS) has appointed Michael Bordainick as Senior Vice President of Commercial Operations, effective January 13, 2022. Bordainick brings two decades of operational and marketing experience, having previously held key roles at Alcon and Kimberly-Clark. His focus will be on enhancing the company’s commercial programs, including direct-to-consumer marketing initiatives for Lap-Band and reshapecare. This appointment aims to accelerate growth and bolster revenue generation strategies amidst rising global health challenges related to obesity.
ReShape Lifesciences (Nasdaq: RSLS) will present a live company overview at VirtualInvestorConferences.com on December 16, 2021, at 2:00 pm ET. CEO Bart Bandy and CFO Tom Stankovich invite investors to participate and ask questions in real-time. An archived webcast will be available for those unable to attend live. Attendees are encouraged to pre-register and complete an online system check. ReShape Lifesciences focuses on weight loss and metabolic health solutions, including the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System.
ReShape Lifesciences Inc. (NASDAQ:RSLS) announced the success of its national advertising campaign and Virtual Media Tour, achieving key performance indicators and exceeding expectations.
In the first five weeks, scheduled patient consults rose by 520%, indicating strong market response. The Lap-Band, a minimally invasive weight-loss solution, is FDA-approved and widely reimbursed. The campaign aims to address obesity, exacerbated by the Covid pandemic, with engaging patient testimonials to resonate with consumers. Ads will now run on additional platforms, enhancing visibility.
ReShape Lifesciences (RSLS) reported Q3 2021 revenue of $3.7 million, a 2.9% increase year-over-year, with a 29.2% revenue growth for the nine-month period. The company launched a national marketing campaign and expanded its product line with new supplements. However, operating expenses surged to $17.1 million due to significant one-time costs, including $10.7 million in stock-based compensation. G&A expenses reached $12 million, reflecting merger-related costs. Despite these challenges, cash and cash equivalents stood at $29.3 million as of September 30, 2021.
ReShape Lifesciences (NASDAQ:RSLS) will report its third quarter 2021 financial and operational results on November 11, 2021, at 8:30 a.m. ET. A webinar discussing these results will be available at 8:45 a.m. ET on the same day, accessible via the Investor Relations page of the ReShape website.
The company focuses on weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System. ReShape also provides a virtual weight-management program and an online wellness marketplace.
FAQ
What is the current stock price of Reshape Lifesciences (RSLS)?
What is the market cap of Reshape Lifesciences (RSLS)?
